DON LYNN GIBBONS to Mitogen-Activated Protein Kinase Kinases
This is a "connection" page, showing publications DON LYNN GIBBONS has written about Mitogen-Activated Protein Kinase Kinases.
Connection Strength
2.587
-
Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers. Nat Commun. 2021 05 10; 12(1):2606.
Score: 0.643
-
Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-Mesenchymal Transition in NSCLC. Cancer Res. 2021 03 01; 81(5):1398-1412.
Score: 0.628
-
Phase I/II Trial of Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC: Early Trial Report. Clin Lung Cancer. 2020 07; 21(4):384-388.
Score: 0.593
-
ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism. Sci Transl Med. 2019 03 13; 11(483).
Score: 0.554
-
MEK inhibition invigorates chemoimmunotherapy by tumor mitophagy-induced CXCL10 expression. Cell Rep Med. 2022 01 18; 3(1):100506.
Score: 0.169